LadRx (CYTR) Stock Price, News & Analysis

Company Overview

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.09 to $0.10
• 52-Week Range: N/A
• Volume: 4,000 shs
• Average Volume: 99,706 shs
• Market Capitalization: $4.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYTR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of LadRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LadRx investors own include Costco Wholesale (COST), Chipotle Mexican Grill (CMG), Caterpillar (CAT), Bristol-Myers Squibb (BMY), Boeing (BA), Broadcom (AVGO) and Alpha Metallurgical Resources (AMR).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CYTR
• CIK: N/A
• Web: www.cytrx.com
• Phone: (310) 826-5648
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 45,037,000
• Free Float: N/A
• Market Cap: $4.14 million
• Optionable: Not Optionable
• Beta: N/A